Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2024; 30(25): 3182-3184
Published online Jul 7, 2024. doi: 10.3748/wjg.v30.i25.3182
Back to the drawing board: Overview of the next generation of combination therapy for inflammatory bowel disease
Jeffrey A Lowell, Michael J Farber, Keith Sultan
Jeffrey A Lowell, Department of Medicine, Zucker School of Medicine at Hofstra, North Shore University Hospital-Long Island Jewish Medical Center, Manhasset, NY 11030, United States
Michael J Farber, Preclinical Studies, New York Institute of Technology College of Osteopathic Medicine, Glen Head, NY 11545, United States
Keith Sultan, Division of Gastroenterology, Northwell Health, North Shore University Hospital and Long Island Jewish Medical Center, Great Neck, NY 10021, United States
Author contributions: Lowell JA, Farber MJ, and Sultan K conceptualized the editorial response; Lowell JA drafted the original manuscript. All authors edited subsequent revisions.
Conflict-of-interest statement: The authors declare no conflicts of interest in relation to this letter.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jeffrey A Lowell, MD, PhD, Doctor, Department of Medicine, Zucker School of Medicine at Hofstra, North Shore University Hospital-Long Island Jewish Medical Center, 300 Community Drive, Manhasset, NY 11030, United States. jlowell@northwell.edu
Received: May 1, 2024
Revised: May 27, 2024
Accepted: June 12, 2024
Published online: July 7, 2024
Processing time: 61 Days and 5.6 Hours
Core Tip

Core Tip: Triantafillidis et al thoroughly collate important studies summarizing the available evidence supporting the combination of various therapeutics used in the treatment of inflammatory bowel disease (IBD). Specifically highlighted is the importance of exploring combination therapy with biologics and immunomodulators, and in particular the emerging role of dual-biologic therapy (DBT). Given that current evidence for DBT is limited and new biologics continue to be developed, there is an urgent need for high-quality prospective trials to establish new treatment paradigms for the next generation of IBD care.